Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Mavorixafor’s Phase III trial for chronic neutropenia is on track with a reduced enrollment target and strong FDA alignment. X4 Pharmaceuticals says operational changes improved enrollment, with a new study to address G-CSF reduction, and a commercial launch targeted for late 2028 or early 2029.
XFOR says its Phase III trial for chronic neutropenia is on track to complete enrollment by year-end. Top-line data is expected in early 2028, with a new G-CSF titration study planned and commercial launch targeted for late 2028 or early 2029.